Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klümpen, Stephen L Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W Valle, Li Yu, Usha Malhotra, Abby B Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Immaculada Ales Diaz, Gustavo Alves, Sumitra Anand, Cagatay Arslan, Jamil Asselah, Eric Assenat, Francine Aubin, Li-Yuan Bai, Yuxian Bai, Susan Bates, Stephen Begbie, Irit Ben-Aharon, Nina Beri, Marie-Luise Berres, Jean-Frederic Blanc, Ivan Borbath, Robert Bordonaro, Giovanni Brandi, Adam Burgoyne, Kritiya Butthongkomvong, Ke Cao, Marcela Carballido, Marcos Camandaroba, Stephan Lam Chang, Jen-Shi Chen, Ming-Huang Chen, Xiaoming Chen, Ashley Cheng, Tai-Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joelle Collignon, Antonio Cubillo Gracian, Sarah Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith De Vos, Maria Diab, Jacob Easaw, Martin Eatock, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernandez, Richard Finn, Fabio Franke, Masayuki Furukawa, Olumide Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gumus, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoglu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Juneul Hwang, Mevlude Inanc, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jimenez Fonseca, Warren Joubert, Jitlada Juengsamarn, Diego Kaen, Masahi Kanai, Stefan Kasper-Virchow, Ghazaleh Kazemi, Fergal Kelleher, Robin Kelley, Jin Won Kim, Jong Gwang Kim, Ana Beatriz Kinupe Abrahao, Heinz Klumpen, Mark Kochenderfer, Fatih Kose, Ho Ching Lam, Choong-kun Lee, Hyun Woo Lee, Margaret Lee, Myung Ah Lee, Wai Man Sarah Lee, Samuel Le Sourd, Dongliang Li, Wei Li, Houjie Liang, Tingbo Liang, Chun Sen Lim, Brian Lingerfelt, Charles Lopez, John Low, Teresa Macarulla Mercade, David Malka, Yimin Mao, Gianluca Masi, Steven McCune, Ray McDermott, Elaine McWhirter, Guillermo Mendez, Michele Milella, Tomonori Mizutani, Camila Moniz, Luisa Morales, Andres Jesús Munoz Martin, Bruno Nervi, Nuttapong Ngamphaiboon, Sang Cheul Oh, Berna Oksuzoglu, Darryl Outlaw, Mustafa Ozguroglu, Ozgur Ozyilkan, Claudio Painemeal, Yueyin Pan, Chuang Peng, Caroline Petorin, Denis Pezet, Derek Power, Shukui Qin, Aflah Roohullah, Hyewon Ryu, Pamela Salman, Rita Sasidharan, Taroh Satho, Kornelius Schulze, Martin Scott-Brown, Ruben Segovia, Thomas Seufferlin, Salvatore Siena, Isabelle Sinapi, Cristina Smolenschi, Tianqiang Song, Aumkhae Sookprasert, Nopadol Soparattanapaisarn, Naureen Starling, Stacey Stein, Salomon Stemmer, Haichuan Su, Rie Sugimoto, Thatthan Suksombooncharoen, Vincent Tam, Ai Lian Tan, Chih Kiang Tan, Suebpong Tanasanvimon, Giuseppe Tonini, Giampaolo Tortora, Akihito Tsuji, Rodrigo Uribe, Marino Venerito, Helena Verdaguer Mata, Ana Paula Victorino, James Wade, Dirk Thomas Waldschmidt, Lu Wang, Wan Zamaniah Wan Isahk, Harpeet Wasan, Rui Weschenfelder, Chun Yin Wong, Yoke Fui Wong, Suayib Yalcin, Patricio Yanez Weber, Xuezhong Yang, Hisateru Yasui, Ozan Yazici, Chia-Jui Yen, Jieer Ying, Wenchang Yu, Haitao Zhao

Publikováno v: The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited

Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2bc96e0f72cde5bf243ad704e6b14
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx

Engraftment of Severe Combined Immune Deficient Mice Receiving Allogeneic Bone Marrow Via In Utero or Postnatal Transfer

Autor: Blazar, B. R., Taylor, P. A., Mcelmurry, R., Tian, L., Panoskaltsis-Mortari, A., Lam, S., Lees, C., Thomas Waldschmidt, Vallera, D. A.

Publikováno v: Scopus-Elsevier

Although in utero transplantation (IUT) has been shown to be effective in treating human severe combined immune deficiency (SCID), the relative merit of IUT as compared with postnatal bone marrow transplantation (BMT) for SCID is unknown. Therefore,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0482224be06ece8c2a2519a105a628c
https://doi.org/10.1182/blood.v92.10.3949.422k26_3949_3959

Oncogenic collaboration with IL-6 in the induction of spontaneous germinal centers (74.11)

Autor: Timothy Rosean, Van Tompkins, Thomas Waldschmidt, Siegfried Janz

Publikováno v: The Journal of Immunology. 188:74.11-74.11

Multiple myeloma (MM) is the second most common hematological malignancy in the United States, and represents one percent of all cancers. Despite ongoing research, MM remains incurable, with an average life expectancy of five to eight years after dia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45e07ab6570f3f305f3310a34ea25121
https://doi.org/10.4049/jimmunol.188.supp.74.11

Regulation of influenza virus-induced germinal center reactions (130.9)

Autor: Alexander Boyden, Kevin Legge, Thomas Waldschmidt

Publikováno v: The Journal of Immunology. 182:130.9-130.9

Previous work from our laboratory has demonstrated a steady state environment within primary splenic germinal center (GC) reactions as measured by the ratio of non-switched (IgM+) to switched (IgM-) GC B cells, following i.p. challenge with SRBC or p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c50ad0c10ee78a7608b515fa5cb2eacd
https://doi.org/10.4049/jimmunol.182.supp.130.9

The expression of B cell surface receptors. I. The ontogeny and distribution of the murine B cell IgE Fc receptor

Autor: Thomas Waldschmidt, Conrad, D. H., Lynch, R. G.

Publikováno v: Scopus-Elsevier

The ontogenic appearance and lymphoid tissue distribution of the murine B cell IgE FcR (Fc epsilon R) was examined. Flow cytometry was utilized to study the expression of the Fc epsilon R on splenic B cells from mice of increasing age, as well as B c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0f78101de03b78790dfeb190e319b5
https://doi.org/10.4049/jimmunol.140.7.2148